Emisphere Technologies is a Drug Delivery Company whose core business strategy is to partner its proprietary drug delivery technology and license Eligen B12. Our thirty year history has made us the established leader in converting injectable therapeutics into advanced oral formulations. Utilizing our experience in researching, developing and manufacturing a number of fully characterized carriers in our extensive library, our partners leverage our expertise to employ our unique intracellular delivery mechanism to advance their portfolio and create differentiated line extensions. Our capabilities range from early proof of concept, to extensive development and commercial capabilities.
Emisphere’s technology can enhance the clinical profile of both pre-market and currently marketed products. Further, our broad-based proprietary oral drug delivery platform provides significant increases in bioavailability, facilitates the enhanced absorption of small and large molecules without altering their chemical form, and maintains their biological integrity or pharmacological properties. Finally, it is especially useful for oral delivery of peptides, proteins, oligonucleotides and oligosaccharides.
Potential Application of the Eligen® Technology
We believe that the Eligen® drug delivery technology is well suited to facilitate the safe and effective oral absorption of emerging peptides and biologics products that are typically only available as injectibles or are currently under development. We believe that these products represent tremendous promise for realizing improvements in healthcare and growth in the industry. In the cases that such molecules are delivered by injection due to limited benefits, our technology may increase the benefit of the therapy by improving bioavailability, absorption or by decreasing time to onset of action.
- In the cases that such molecules are delivered by injection due to limited benefits, our technology may increase the benefit of the therapy by improving bioavailability, absorption or by decreasing time to onset of action.
- The Eligen® Technology can make it possible to deliver certain therapeutic molecules orally without altering their chemical form or biological activity.
- The Eligen® Technology can be applied to other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal.
- Eligen® “carriers”, enable the transport of therapeutic molecules across the mucous membranes of the gastrointestinal tract, to reach the tissues of the body where they can exert their intended pharmacological effect.
- Our development efforts are conducted internally or in collaboration with corporate development partners.
- Typically, the drugs that we target are at an advanced stage of development, or have already received regulatory approval, and are currently available on the market.
David Gschneidner Ph.D.
Vice President, Carrier R&D
As Emisphere’s Lead Chemist, Dr. Gschneidner is responsible for developing a better understanding of the Eligen® Technology. Dr. Gschneidner joined Emisphere in 1996 as a Medicinal Chemist and over the years has been involved in the design, synthesis, scale-up and manufacture of Emisphere carriers. Other responsibilities have included overseeing carrier screening and serving as a technical liaison to Emisphere’s partners. Previously, Dr. Gschneidner worked as research scientist at Cytec and as a post-doctoral fellow at the University of Colorado, Boulder.
Dr. Gschneidner holds a Ph.D. in Organic Chemistry from University of Wisconsin, Madison and a Bachelor of Science in Chemistry from Iowa State University. Dr. Gschneidner has authored a number of scientific communications, including peer reviewed scientific publications and national conference presentations. He is an inventor on twenty-four U.S. patents.
Director of Finance
Joined Emisphere in 2015, Senior Finance Executive with 30+ years in Finance Management and Financial Systems Design, Implementation, and Management. A graduate of William Paterson University with a BS in Accounting and Finance.
Primary work history includes Finance management positions in a variety of industries including office equipment and automation (Ricoh Corporation), information technology outsourcing (IBM), insurance unwriting & rating software (Cover-All Technologies), and highly secured electronic financial market information (British Telecom/BTRadianz) managing day-to-day accounting functions, internal budgeting, coordinating with auditors and Sarbanes-Oxley consultants, and SEC reporting. Worked for 10+ years creating process improvements in conjunction with implementing Oracle Financials in client companies and organizations in a variety of industries such as Telecommunications (Nynex/Bell Atlantic/Verizon), Insurance (Aetna), Publishing (Philadelphia Inquirer), Health Care (Danbury Hospital & Howard University Hospital), Pharmaceuticals (Merck) , Entertainment (EMI), Manufacturing (Carpenter Technologies), and Higher Education (George Washington University). Role in Emisphere Technologies effectively taps prior experiences to contribute solid and practical financial insight into diverse business opportunities and challenges as they arise as well as manage and maintain the day-to-day accounting needs of the company.
Louis Stamatellos, BS Ch.E, MBA
Director, Global Supply
Senior Operations and Supply Chain Management Executive with 30+ years in Life Sciences with established relationships in the academic, private and public sectors. Primary work history includes, increasingly responsible domestic and international roles (primarily with Merck and Co., Inc. and Novartis Pharma AG) throughout the value chain in chemical, pharmaceutical and medical device manufacturing, pharmaceutical operations management, warehousing and distribution, logistics, customer relationship management, trade channel management and sales & operations planning. In depth understanding of product lifecycle and portfolio management, quality assurance, sales and marketing support, finance, tax, and regulatory affairs. Global leadership role in the creation of an operations and supply chain organization in support of the start-up and commercialization of a first of its kind living skin tissue equivalent with a 5 day shelf life. Previous public sector role of Executive Assistant to the US Postmaster General, providing advice and guidance in the areas of business and project planning and future roles of the USPS in the age of electronic mail. Ongoing academic role in partnership with the US Department of Homeland Security with regard to the responsiveness of the US healthcare supply chain in times of challenge by natural disaster or terrorist threat. Senior advisor role with start-up consultancy focused on assessing organization maturity levels and effectiveness as is relates to value creation, readiness for change and outside in market focus. Long term participant in the Council for Excellence in Government, successor non-profit organization to the President’s Commission on Executive Exchange. Role in Emisphere Technologies, effectively taps historic roles in novel pharmaceutical industry start-up projects where there is a need to establish business processes, required resources, adequate organizational structure, long term supplier relationships and unwavering customer focus. These capabilities extend to effectively managed contract services including CMO’s and 3PL’s.
Quality Management Executive
Quality Management Executive with extensive experience in Quality Assurance/Control/ Regulatory compliance both US and International. Strong understanding of the overall Pharmaceutical/Cosmetic/ Veterinarian/Device/Diagnostics industries. Travelled extensively in the US and abroad.
Worked for Hoffman-La Roche, Searle in South Korea, American Home Products, Whitehall, and Sanofi Inc.
Retired from Sanofi as Vice President for North America and member of the Executive Committee with dual reporting into the US and France.
John D. Harkey Jr.
John D. Harkey Jr.
John D. Harkey Jr., has been Director of the Company since April 2006. Mr. Harkey is Chairman and Chief Executive Officer of Consolidated Restaurant Operations, Inc. He currently serves on the Board of Directors, Audit Committee and Compensation Committee of Loral Space & Communications, Inc. (NASDAQ:LORL), and on the Board of Directors of Emisphere Technologies, Inc. (OTCBB:EMIS). Mr. Harkey is formerly the Chairman of the Board of Regency Gas Partners, L.P. (NYSE:RGP) has served on the Board of Directors of Energy Transfer Equity, LP (NYSE:ETE) and Energy Transfer Partners, LP (NYSE:ETP). He formerly served on Board of Directors of Leap Wireless International, Inc. (NASDAQ:LEAP) which was acquired by AT&T. He is also co-founder and formerly Executive Chairman of the Board of AveXis, Inc. (NASDAQ:AVXS). He serves on the Board of Directors of the Baylor Health Care System Foundation, The University of Texas System Chancellor’s Council Executive Committee and is a member of the McCombs School of Business Advisory Board at the University of Texas at Austin. He serves on the President’s Development Council of Howard Payne University, the CEO Advisory Board of Dallas Arboretum and the Executive Board of Circle Ten Council of the Boy Scouts of America, and is a member of the Young Presidents’ Organization. Mr. Harkey obtained a B.B.A. in Honors Finance and, a J.D. from the University of Texas at Austin and a M.B.A. from Stanford University School of Business. Mr. Harkey’s entrepreneurial background, his qualification as a financial expert, and his business and leadership experiences in a range of different industries make him an asset to our Board of Directors.
Tim McInerney has been a Director of the Company since March 2012. Mr. McInerney is a principal at Two River and a Partner of Riverbank Capital Securities, Inc. From 1992 to March 2007, Mr. McInerney was a Managing Director of Paramount BioCapital, Inc. where he oversaw the overall distribution of Paramount’s private equity product. Prior to 1992, Mr. McInerney was a research analyst focusing on the biotechnology industry at Ladenburg, Thalman & Co. Prior to that, Mr. McInerney held equity sales positions at Bear Stearns & Co. and Shearson Lehman Brothers, Inc. Mr. McInerney also worked in sales and marketing for Bristol-Myers Squibb. Mr. McInerney is currently Chairman of the Board of Directors of Insite Vision, Inc., (OTCBB: INSV), and is a member of the Board of Directors of ZIOPHARM, Inc., (NASDAQ: ZIOP), and Edgemont Pharmaceuticals, LLC. He formerly served on the Board of Directors of Manhattan Pharmaceuticals, Inc., (OTCBB: TGTX). Mr. McInerney received his B.S. in pharmacy from St. John’s University at New York. He also completed a post-graduate residency at the New York University Medical Center in drug information systems. Mr. McInerney’s knowledge of the pharmaceutical industry and capital markets, and affiliations with the financial community make him an asset to our Board of Directors.
Mark H. Rachesky, M.D.
Mark H. Rachesky, M.D.
Mark H. Rachesky, M.D., has been a director of the Company since 2005. Dr. Rachesky is the founder and President of MHR Fund Management LLC, an investment manager of various private investment funds that invest in inefficient market sectors, including special situation equities. Dr. Rachesky is currently the Non-Executive Chairman of the Board of Directors of Loral Space & Communications Inc. (NASDAQ:LORL), Lions Gate Entertainment Corp. (NYSE: LGF), and Telesat Canada. He also serves on the Board of Directors of Navistar International Corporation (NYSE: NAV) and Titan International, Inc. (NYSE: TWI). Dr. Rachesky is a graduate of Stanford University School of Medicine and Stanford University School of Business. Dr. Rachesky graduated from the University of Pennsylvania with a major in Molecular Aspects of Cancer. Dr. Rachesky’s extensive investing and financial background, his thorough knowledge of capital markets and his training as an M.D., make him an asset to our Board of Directors.
Timothy G. Rothwell
Timothy G. Rothwell
Timothy G. Rothwell has been the Chairman of Emisphere Technologies Inc. (OTC: EMIS), since early 2012 and prior to that a Director of the Company from late 2009. Mr. Rothwell is also the Chairman of Speracura LLC, a healthcare consulting company from 2009 and the President of the SDHB PHEOPARA Coalition from 2016.
Mr. Rothwell was formerly Chairman of Sanofi from February 2007 to October 2009 in the U.S. He also served as Chief Executive Officer and President of Sanofi-Aventis from September 2004 to February 2007. Mr. Rothwell oversaw all domestic commercial operations as well as the coordination of Industrial Affairs and Research and Development activities in the U.S. From May 2003 to September 2004, Mr. Rothwell was President and Chief Executive Officer of Sanofi-Synthelabo, Inc. and was instrumental in the formation of Sanofi-Aventis U.S. in 2004. Prior to that, from January 1998 to May 2003, he served in various capacities at Pharmacia, including as President of the company’s Global Prescription Business. From January 1995 to January 1998, Mr. Rothwell also served as worldwide President of Rhone-Poulenc Rorer Pharmaceuticals and President of the company’s Global Pharmaceutical Operations. In his long career, Mr. Rothwell has also served as Chief Executive Officer of Sandoz Pharmaceuticals, Vice President of Global Marketing and Sales at Burroughs Wellcome, and Senior Vice President of Marketing and Sales for the U.S. for Squibb Corporation which later became a Division of Bristol-Myers Squibb.
Mr. Rothwell holds a Bachelor of Arts from Drew University and earned his J.D. from Seton Hall University.
He formerly served on the PhRMA Board of Directors, as well as the Institute of Medicine’s Evidence-Based Medicine roundtable, the CEO Roundtable on Cancer, the Healthcare Businesswoman’s Association Advisory Board, the Board of Trustees for the Somerset Medical Center Foundation, the Board of Trustees for the HealthCare Institute of New Jersey, as a Trustee of the Corporate Council for America’s Children at the Children’s Health Fund, the Board of Directors of Agenus (NASDAQ: AGEN), the Board of Directors of Akrimax Pharmaceuticals LLC, Chairman of the Board of Directors of Archimedes Pharma LLC , Chairman of the Board of Directors of New American Therapeutics, and a member of the Board of Visitors for Seton Hall Law school.
He also served as the Chairman of the Pheo Para Alliance from 2009 to 2014 which is a non-profit organization dedicated to helping patients who suffer from pheochromocytoma and paraganglioma.
Michael Weiser, M.D., Ph.D.
Michael Weiser, M.D., Ph.D.
Michael Weiser M.D., Ph.D. has been a director of the company since 2005.
Dr. Weiser is currently founder and co-chairman of Actin Biomed, a New York-based healthcare investment firm advancing the discovery and development of novel treatments for unmet medical needs.
Prior to founding Actin Biomed in December 2006, Dr. Weiser was the Director of Research at Paramount BioCapital where he was responsible for the scientific, medical and financial evaluation of biomedical technologies and pharmaceutical products under consideration for development.
Dr. Weiser completed his Ph.D. in Molecular Neurobiology at Cornell University Medical College and received his M.D. from New York University School of Medicine. He performed his post-graduate medical training in the Department of Obstetrics and Gynecology at New York University Medical Center. Dr. Weiser also completed a Postdoctoral Fellowship in the Department of Physiology and Neuroscience at New York University School of Medicine and received his B.A. in Psychology from University of Vermont.
Dr. Weiser is a member of The National Medical Honor Society, Alpha Omega Alpha, American Society of Clinical Oncology, American Society of Hematology and Association for Research in Vision and Ophthalmology. In addition, Dr. Weiser has received awards for both academic and professional excellence and is published extensively in both medical and scientific journals.
Dr. Weiser also currently serves on the board of directors for Ziopharm Oncology, Inc., (NASDAQ: ZIOP), as well as several privately held companies.
Dr. Weiser previously served as a director of Chelsea Therapeutics International, (NASDAQ: CHTP), Hana Biosciences, Inc., (currently known as Talon Therapeutics, Inc., OTCBB: TLON.OB), Manhattan Pharmaceuticals, Inc., (OTCBB: TGTX), and Vioquest Pharmaceuticals, Inc., (VOQP: OTC US).
Dr. Weiser has an M.D. and a Ph.D., his scientific, business and financial experiences, as well as his knowledge of the healthcare industry, capital markets, pharmaceutical products and biomedical technology development make him an asset to our Board of Directors.